PMID: 7539960Jun 15, 1995Paper

Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell

Transplantation
K TamuraK Shimomura

Abstract

FK506 (tacrolimus) is a strong immunosuppressant: it has been approved as a drug for liver transplantation in Japan, the United States, and the United Kingdom. One of its main adverse effects is hyperglycemia. Thus, in this study, we investigated the mechanism and the reversibility of the hyperglycemia caused by FK506. FK506 did not affect the glucose uptake by insulin into rat strio-muscle cell line, but suppressed insulin production in rat insulinoma cells. Two-week oral administration of FK506 at 10 mg/kg/day suppressed insulin production time-dependently at the transcriptional step in pancreatic beta-cells, while glucagon content in pancreatic alpha-cells was not affected. When FK506 administration was stopped in these rats, insulin mRNA transcription and insulin production returned to normal. This recovery indicates that the adverse effect of FK506 on the pancreas is reversible. A high content of FK506 binding protein-12 (FKBP-12) in the pancreatic beta-cells was confirmed by immunostaining with anti-human FKBP-12 mAb, but the content was less in the pancreatic alpha-cells and almost negligible in the acinar cells. In contrast, a high content of calcineurin in the pancreatic alpha-cells was confirmed by using anti-calcineu...Continue Reading

Citations

Dec 3, 2005·Pharmaceutical Research·Pleunie P M RoodMassimo Trucco
Apr 9, 1998·Transplantation Proceedings·M D BrendelR G Bretzel
Mar 7, 2002·Diabetes Research and Clinical Practice·Tetsushi ToyonagaEiichi Araki
Jan 8, 2005·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Roy D BloomK Rajender Reddy
Feb 27, 2009·Reproductive Biology and Endocrinology : RB&E·Breno H CaneguimEstela Sasso-Cerri
Nov 6, 2007·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Yoshitaka TayamaKenji Kihira
Apr 1, 2014·The Journal of Endocrinology·Henrik OrtsäterÅke Sjöholm
Jun 3, 2005·Current Diabetes Reports·Moro O SalifuSamy I McFarlane
Jul 31, 2009·Current Diabetes Reports·Vittoria BonatoMario Carmellini
Jan 5, 2005·The Journal of Clinical Investigation·Massimo Trucco
Dec 8, 2010·Proceedings of the National Academy of Sciences of the United States of America·Lingling Duan, Melanie H Cobb
Apr 7, 2006·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·M LoebeD J Hamilton
Sep 12, 2006·Trends in Biotechnology·Lorenzo PasqualiSteven Ringquist
Dec 22, 2011·Diabetes Care·Lidia GhisdalDaniel Abramowicz
Nov 5, 2010·Nihon Rinshō Men'eki Gakkai kaishi = Japanese journal of clinical immunology·Yoshiharu Amasaki
Aug 2, 2005·Biochemical and Biophysical Research Communications·Susumu TanakaYuzuru Kubohara
Apr 16, 2004·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Quanxing WangXiao-Kang Li
Jun 9, 2005·Transplantation·Johannes P van HooffElly M van Duijnhoven
Aug 24, 2006·Transplantation·Jennifer L LarsenFrederick G Hamel
May 29, 2004·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Mariana Markell
May 18, 2017·Clinical Pharmacology and Therapeutics·H A ChakkeraB Kaplan
Jul 9, 2004·Transplantation·Christoph D DieterleRüdiger Landgraf
Mar 17, 2001·Diabetic Medicine : a Journal of the British Diabetic Association·S A WhiteM L Nicholson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Ataxia telangiectasia (MDS)

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.